Priti Sahgal
Psychiatry · Los Alamitos, CANPI 1457507436
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 497 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 497 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Sunovion Pharmaceuticals Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$895
- AbbVie$746
- Otsuka America Pharmaceutical, Inc.$649
- Lundbeck LLC$622
- plus $4K from 26 others
What the payments were for
- Food & beverage$9,524100%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 77 | $1,326 |
| Sunovion Pharmaceuticals Inc. | 63 | $1,103 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 53 | $895 |
| AbbVie(2 entities) | 35 | $746 |
| Otsuka America Pharmaceutical, Inc. | 39 | $649 |
| Lundbeck LLC | 25 | $622 |
| Vanda Pharmaceuticals Inc. | 30 | $589 |
| Corium, LLC | 26 | $527 |
| Alkermes, Inc. | 17 | $453 |
| Tris Pharma Inc | 17 | $296 |
| Almatica Pharma LLC | 15 | $278 |
| Axsome Therapeutics, Inc. | 11 | $272 |
| Supernus Pharmaceuticals, Inc. | 17 | $267 |
| Neos Therapeutics, LP | 12 | $233 |
| Neurocrine Biosciences, Inc. | 8 | $198 |
| Johnson & Johnson | 7 | $186 |
| Shire North American Group Inc | 8 | $137 |
| Adlon Therapeutics L.p. | 7 | $127 |
| Collegium Pharmaceutical, Inc. | 5 | $103 |
| Teva Pharmaceuticals USA, Inc. | 4 | $96 |
| Ironshore Pharmaceuticals Inc. | 5 | $83 |
| Alfasigma USA, Inc. | 1 | $72 |
| E.r. Squibb & Sons, L.L.C. | 2 | $50 |
| Merck | 2 | $45 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Eisai Inc. | 2 | $38 |
| Noven Therapeutics, LLC | 2 | $28 |
| OWP Pharmaceuticals, Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Neuronetics, Inc. | 1 | $19 |
| Aytu Biopharma, Inc. | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$520
- ARISTADA INITIO$130
- VRAYLAR$121
How this compares
$9,558 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 21 | $40,751 |
| TrintellixVortioxetine Hydrobromide | 23 | $21,631 |
| RexultiBrexpiprazole | 13 | $16,659 |
| Ramelteon | 28 | $4,053 |
| Lisdexamfetamine Dimesylate | 15 | $3,826 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 54 | $3,482 |
| Vilazodone Hcl | 33 | $2,692 |
| Ziprasidone Hcl | 19 | $2,570 |
| Asenapine Maleate | 15 | $2,285 |
| Oxcarbazepine | 26 | $1,888 |
| Duloxetine Hcl | 50 | $1,416 |
| Lamotrigine | 66 | $1,395 |
| Quetiapine Fumarate | 45 | $1,294 |
| Buspirone Hcl | 62 | $1,050 |
| Bupropion XlBupropion Hcl | 63 | $996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $746 | $40,75121 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,326 | $21,63123 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $649 | $16,65913 claims |
| Almatica Pharma LLCSertraline Hcl | $278 | $93682 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Los Alamitos
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.